Document Detail

Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 2.
MedLine Citation:
PMID:  18592813     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the use of alternative therapies for chronic urticaria refractory to first-line treatments in an evidence-based manner. DATA SOURCES: MEDLINE searches were performed cross-referencing urticaria with the names of multiple therapies. Articles were then reviewed for additional citations. Articles published after 1950 were considered. STUDY SELECTION: All articles, including case reports, were reviewed for soundness and relevance. RESULTS: Experience has been reported for a wide variety of alternative therapies in the treatment of chronic idiopathic and physical urticarias. Evidence for most agents is limited to anecdotal reports. The therapies reviewed are also categorized based on criteria of safety, efficacy, convenience, and cost. The less preferred alternative agents in the second part of this review are divided between third-line therapies and others that are unable to be firmly recommended or that seem promising but lack substantial evidence. CONCLUSIONS: Third-line alternative agents should be considered in patients with chronic urticaria who are severely affected and unresponsive to antihistamines and second-line therapies. Although monitoring for toxicity is important in management with third-line agents, safety remains favorable for most agents compared with corticosteroids.
Matt Morgan; David A Khan
Related Documents :
18462283 - Assessing walking speed in clinical research: a systematic review.
1543313 - Vagal reflexes referred from the upper aerodigestive tract: an infrequently recognized ...
20222953 - Kikuchi fujimoto disease associated with cryptogenic organizing pneumonia: case report ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  100     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-07-02     Completed Date:  2008-08-18     Revised Date:  2009-01-29    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  517-26; quiz 526-8, 544     Citation Subset:  IM    
Division of Allergy and Immunology, University of Texas Southwestern, Dallas, Texas 75390-8859, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgens / adverse effects,  therapeutic use
Anticoagulants / adverse effects,  therapeutic use
Calcium Channel Blockers / adverse effects,  therapeutic use
Chronic Disease
Cyclophosphamide / adverse effects,  therapeutic use
Drug Monitoring
Immunoglobulins, Intravenous / adverse effects,  therapeutic use
Methotrexate / adverse effects,  therapeutic use
Organogold Compounds / adverse effects,  therapeutic use
Phototherapy / adverse effects
Plasmapheresis / adverse effects,  methods
Urticaria / drug therapy,  therapy*
Reg. No./Substance:
0/Androgens; 0/Anticoagulants; 0/Calcium Channel Blockers; 0/Immunoglobulins, Intravenous; 0/Organogold Compounds; 50-18-0/Cyclophosphamide; 59-05-2/Methotrexate
Comment In:
Ann Allergy Asthma Immunol. 2008 Dec;101(6):647   [PMID:  19119713 ]
Ann Allergy Asthma Immunol. 2008 Nov;101(5):555; author reply 555-6   [PMID:  19055215 ]
Ann Allergy Asthma Immunol. 2008 Nov;101(5):556   [PMID:  19055216 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Confirming the structure of the Why Do You Smoke? Questionnaire: a community resource for adolescent...
Next Document:  Radiologic outcomes in children with chronic rhinosinusitis and ostiomeatal complex obstruction afte...